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Abstract
Hyperhomocysteinemia in patients with diabetes mellitus (DM) has been proposed as a new risk factor for coronary artery
disease (CAD). Due to the prevalence of DM and CAD in the Iranian population and the relatively high economic burden,
research on these new risk factors sounds necessary. This study investigated the relationship between hyperhomocysteinemia and
coronary heart disease in patients with type 2 diabetes. This study was a hospital-based cross-sectional study performed on 100
diabetic patients with indications of coronary artery angiography. After the measurement of serumHbA1c and homocysteine, the
patients went through coronary angiography and, based on the results, were divided into two groups of normal and obstructed
coronary arteries. Serum homocysteine and other related risk factors were further compared between the two groups. The mean
serum homocysteine of patients was 13.18 ± 3.64 μmol/L in general and 15.02 ± 3.7 μmol/L in those with coronary artery
obstruction. With hyperhomocysteinemia defined as serum homocysteine of ≥ 14 μmol/L, 48% of diabetic patients had hyper-
homocysteinemia, of which 83% had coronary artery obstruction. The relationship between serum homocysteine and coronary
artery obstruction was significant (P < 0.001). The serum homocysteine was the highest in patients with three-vessel involvement
(15.39 ± 3.5 μmol/L), which was significantly higher than those with normal coronary arteries (P < 0.001). The mean serum
homocysteine of diabetic patients (type II) with coronary artery disease was significantly higher than those with normal coronary
arteries. It was also significantly higher in patients with three-vessel involvement than those with no vessel involvement.
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Introduction
According to the last WHO fact sheet on cardiovascular dis-
ease (updated January 2015), cardiovascular diseases are
responsible for 17.5 million deaths annually. In both the de-
veloped and most of the developing countries, it is the reason
for nearly one-third of adult deaths. Of these deaths, 7.4 mil-
lion are due to coronary heart disease and 6.7 million are
caused by stroke. Current studies indicate that it is a major
health problem in the eastern Mediterranean region and
Middle Eastern countries including Iran (Mendis et al. 2015).
The atherosclerosis of coronary arteries is one of the most
prevalent diseases of the last century, which is associated with
high annual morbidity and mortality. In diabetic patients, the
prevalence and mortality rate of coronary artery diseases are
almost two to three times higher than the general population
(Kannel and McGee 1979). In Iran, diabetes is a major public
health problem and most of the patients are not even aware of
their disease (Hadaegh et al. 2008). The reported prevalence
of diabetes in Iran based on a national study of risk factors for
non-communicable diseases was 7.7%, equivalent to 2million
patients in the Iranian population aged between 25 and
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64 years in 2008 (Esteghamati et al. 2008). The International
Diabetes Federation has also reported the estimated preva-
lence of diabetes in Iran in 2013 to be 8.43% in the Iranian
population aged 20 to 79 years (Unwin et al. 2013). Diabetes
mellitus imposes both direct and indirect costs on the patients,
which is much higher in comparison to many other diseases.
There are a few documented studies on the assessment of costs
associated with diabetes mellitus in Iran. The mean diabetes-
related expenditure per Iranian with diabetes (USD) was re-
ported to be 471 USD by the International Diabetes
Federation (IFD Diabetes Atlas, 6th edition) (Unwin et al.
2013). Based on the last released research of the American
Diabetes Association onMarch 6, 2013, on economic costs of
diabetes in the US, the estimated total economic cost of diag-
nosed diabetes has risen from $174 billion (in 2007, dollars) to
$245 billion in 2012, which shows a 41% increase. This em-
phasizes the fact that diabetes imposes a major burden on the
society (American Diabetes Association 2013).
Besides the common classic risk factors known for coro-
nary artery diseases, newer risk factors, such as serum homo-
cysteine level, lipoprotein (a), and C-reactive protein, have
been proposed. The role of these novel cardiovascular risk
factors is elucidated more and more every day (Antoniades
et al. 2009; Humphrey et al. 2008). Moreover, it has been
shown that lipoprotein (a), homocysteine, and apolipoprotein
(a) polymorphism are each independently associated with si-
lent coronary artery disease in patients with diabetes mellitus,
type II (Gazzaruso et al. 2002).
In a study byMohammadi et al. in 2005, the serum level of
homocysteine was measured in patients with diabetes mellitus
type II and glucose intolerance, and compared with that of the
control group. However, there was found no significant dif-
ference between them (Mohammadi et al. 2005). In another
cross-sectional study, Sharifkazemi et al. studied the serum
level of homocysteine in 197 Iranian patients who had under-
gone coronary angiography. Hyperhomocysteinemia was
found to be an independent risk factor of coronary artery dis-
ease. In patients without any risk factor, there was a linear
relationship between the serum level of homocysteine and
number of affected coronary arteries (Kazemi et al. 2006).
Sadeghian et al. also studied the serum level of homocysteine
in patients with early coronary artery disease in a cross-
sectional study in 2006. The study was performed on 225
patients younger than 45 years who had undergone coronary
angiography. Early coronary atherosclerosis was evident in
43% of the patients. The serum level of homocysteine was
significantly higher in male patients than the control group
(Sadeghian et al. 2006).
In a study by Gazzaruso et al. in Italy, the serum homocys-
teine level was measured in diabetic patients (type II) who had
silent coronary artery disease. It was shown that the serum
level of homocysteine and lipoprotein (a) is higher in diabetic
patients with coronary artery disease than those without it
(Gazzaruso et al. 2002). Audelin et al. in a review article on
the effect of homocysteine on cardiovascular diseases in dia-
betic patients concluded that hyperhomocysteinemia is only
associated with increased mortality (Audelin and Genest
2001). Hoogeveen et al. studied the relationship between hy-
perhomocysteinemia and cardiovascular diseases in diabetic
patients compared with patients with glucose intolerance and
non-diabetic patients. They measured the morning serum ho-
mocysteine level of 631 white patients aged 50–75 and the
data were matched for sex, age, blood pressure, smoking, and
hypercholesterolemia. However, homocysteine was found to
be a strong risk factor for cardiovascular disease in patients
with diabetes mellitus type II (Hoogeveen et al. 1998). In a
large cohort of 830 patients aged between 45 and 64 years
with diabetes mellitus II, serum homocysteine was found to
be an independent predictor of coronary heart disease death
and all events (Soinio et al. 2004). In another study,
Mojiminiyi et al. studied the relationship of serum homocys-
teine, lipoprotein (a), and C-reactive protein (CRP) to coro-
nary heart diseases in patients with type 2 diabetes mellitus. It
was found that serum homocysteine and CRP are significantly
higher in patients with cardiovascular disease than the control
group (Mojiminiyi et al. 2002). A similar study by Akalin
et al. in Turkey showed that the plasma level of homocysteine
and inflammatory markers in diabetic patients with coronary
atherosclerosis is significantly greater than those without it
(Akalin et al. 2008). Okada et al. also studied the level of
serum homocysteine in Japanese diabetic and non-diabetic
patients, who had undergone coronary angiography. It was
revealed that the degree of coronary stenosis in diabetic pa-
tients with hyperhomocysteinemia is greater than those with
normal serum homocysteine level (Okada et al. 1999).
In this study, the level of serum homocysteine and its rela-
tionship to the atherosclerosis of coronary arteries were stud-
ied in diabetic patients who had undergone coronary angiog-
raphy. Because of the relatively high prevalence of diabetes
mellitus and coronary artery disease in the Iranian population,
the identification and study of the etiologies of coronary ath-
erosclerosis are considered one of the essential health priori-
ties of the country.
Methods
Study participants
This study was a hospital-based cross-sectional study per-
formed on patients with diabetes mellitus type II in order to
study the relationship between hyperhomocysteinemia and
coronary artery obstruction in Iranian diabetic patients. A total
of 100 diabetic patients with indications of coronary artery
angiography who came to the angiography department of
Shahid Mostafa-Khomeini hospital, were included in the
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study. The patients were selected by simple non-random sam-
pling method. All the patients who had renal failure, hypothy-
roidism, rheumatic diseases, drug history of vitamin B12 or
folate combinations, and past history of infection in the last
2 months had been excluded from the study. Diabetes mellitus
was defined as current treatment with insulin or oral hypogly-
cemic agents, or diabetic-range fasting blood sugar according
to the American Diabetes Association criteria (Dormandy
et al. 2005). The indications of coronary artery angiography
were the definitive indications based on AHA/ACC guideline
on coronary angiography (Mann et al. 2014).
The patients were first visited by a cardiologist and after a
full history was elicited from them and the physical examina-
tion, they went through laboratory tests including the mea-
surement of serum homocysteine and HbA1c. The question-
naire of demographic data was filled for all the patients. To
measure the serum level of homocysteine and HbA1c, 5 mL
of fasting blood (10–12 h) was drawn from each patient in
EDTA test tubes. In less than an hour, the blood samples were
centrifuged with a rotation speed of 1550 revolutions per
10 min to separate the sera. An amount of 1.5 mL of each
patient’s serum was separated and used for the measurement
of HbA1c by the kits (Pars-Azmoon, Tehran, Iran) using the
turbidimetry technique. The rest of the serum was kept at −
20 °C. The homocysteine level of these sera was measured by
ELISA kits and using the HPLC device equipped with fluo-
rescence detector (RF-551).
At last the patients went through coronary angiography. All
the angiography films of the patients were interpreted by an
experienced cardiologist. The severity of coronary artery ob-
struction was reported based on the criteria of coronary artery
diseases. Based on the results, the patients were further divid-
ed into two groups: (1) those with obstruction of more than
50% in the main arteries or their branches and (2) those who
had normal coronary arteries as controls.
Statistical analysis and data analysis methods
The statistical analysis of the data was done using SPSS sta-
tistics software package 16 (Hosseini et al. 2016; Sharif et al.
2016; Kashani et al. 2012; Jalali et al. 2016). The tests used for
the analysis of the data were t test, chi-square, and ANOVA
(Lotfi et al. 2016; Nikzad et al. 2013; Kashani et al. 2013). The
results of the study were reported as mean ± standard devia-
tion. The significance level was defined as a P value of less
than 0.05.
Ethical considerations
The goals and all the steps of the study were explained
completely for all the patients. The patients participated in
the study on their own will and they could anytime withdraw
from the study. No charge was imposed on the patients.
Written consent was obtained from all the patients before the
study (Sharif et al. n.d.; Saba et al. 2017; Piroozmand et al.
2017). All procedures performed in studies involving human
participants were in accordance with the ethical standards of
the institutional and national research committee and with the
1964 Helsinki declaration and its later amendments.
Results
A total of 100 patients with diabetes mellitus type II, 60%
male and 40% female (Table 1), were studied. The patients
were aged from 48 to 78 years old with an average age of
64.14 ± 7.18. It was found that 66% of patients have some
degree of coronary artery obstruction, among which 19 pa-
tients (19%) had two and 47 patients (47%) had three-vessel
involvement. It is to be noted that only three patients had one
vessel involvement and because they had evidence of milder
involvement of other vessels, they were considered among
those patients with two-vessel involvement. The average age
of patients with two- and three-vessel involvement was 63.89
± 5.7 and 66.45 ± 7.9, respectively, and that of normal patients
was 61.9 ± 5.6. The mean age of patients with coronary artery
obstruction was significantly higher than that of patients with-
out it (P < 0.01). However, no significant relationship was
found between age and the number of involved vessels.
The past history of hypertension was present in 75% of
patients, 24% were smokers, and 67% had a family history
of cardiovascular diseases in their first-degree relatives. The
complete set of patients’ demographic data is visible in
Table 1. There was not found any significant relationship be-
tween coronary artery obstruction and hypertension, smoking,
and family history of cardiovascular diseases in this study.
The mean serum homocysteine of patients was 13.18 ±
3.64 μmol/L in general (Table 2) and 15.02 ± 3.7 μmol/L in
those with coronary artery obstruction. The relationship be-
tween hyperhomocysteinemia, assuming different definitions,
and coronary artery obstruction is shown in Fig. 1. With hy-
perhomocysteinemia defined as serum homocysteine more
than 14 μmol/L, 48% of diabetic patients (48 patients) had
hyperhomocysteinemia, of which 40 patients (83%) had cor-
onary artery obstruction and 8 (17%) had normal coronary
arteries. With a definition of more than 15 μmol/L, the fre-
quency of hyperhomocysteinemia in diabetic patients was
32%, of which only 3 patients (10%) were normal and the
other 29 (90%) had coronary artery obstruction. There was a
significant relationship between serum homocysteine and cor-
onary artery obstruction (P < 0.001).
As shown in Table 2, serum homocysteine was the
highest in patients with three-vessel involvement (15.39
± 3.5 μmol/L), which was significantly higher than those
with normal coronary arteries (P < 0.001). However, no
s ign i f i c an t d i f f e r ence was found be tween the
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homocysteine level of patients with three- and two-vessel
involvement, and also those with two and no vessel(s) in-
volvement. The mean HbA1c, FBS, and BMI of the pa-
tients were 8 ± 1.38 mmol/L, 162 ± 40.2 mg/dL, and 23.26
± 4.9 Kg/m2, respectively (Table 2). There was found no
significant difference between HbA1c, FBS, and BMI of
the patients with and without coronary artery obstruction.
In 72% of patients, the age of onset of diabetes was
above 50 years, while only in 4% it was below 40 years.
While 41% of patients had a duration of diabetes of more
than 10 years, in 15% it was less than 5 years. Further
data is shown in Table 3. The age of onset and duration of
diabetes were compared between patients with and with-
out coronary artery obstruction but the difference was not
significant.
As shown in Fig. 2, the mean serum homocysteine was
the lowest (10.98 ± 2.43 μmol/L) in patients with an age of
onset of diabetes between 30 and 39 years, and highest
(14.51 ± 3.69 μmol/L) in those with an age of onset above
50 years. However, the difference was not statistically sig-
nificant. Nevertheless, it was found to be the highest (15.1
± 3.9 μmol/L) in those patients with a duration of diabetes
more than 10 years, and the lowest (12.88 ± 2.6 μmol/L) in
those with a duration between 5 and 10 years, with their
difference being significant (P < 0.05) (Fig. 2). There was
found no significant relationship between HbA1c and BMI
and the age of onset and duration.
The mean serum homocysteine of smokers and non-
smokers were 14.1 ± 3.06 and 13.65 ± 3.67 μmol/L, re-
spectively, and the difference between them was not statis-
tically significant. However, there was a significant rela-
tionship between the level of serum homocysteine and
blood pressure (P < 0.05) and in hypertensive patients, it
was higher (14.47 ± 3.7 μmol/L) than normotensive pa-
tients (12.5 ± 2.7 μmol/L).
Discussion
The atherosclerosis of coronary arteries is one of the most
common diseases of the last century, which is associated with
a high mortality rate. Hyperhomocysteinemia has been
established as an independent risk factor of atherosclerosis
(Perry et al. 1995; Atkinson et al. 2008; Shekelle 2006). It is
also known that diabetes mellitus hastens the development of
atherosclerosis itself (Kasper et al. 2015). To clarify the rela-
tionship between hyperhomocysteinemia and development of
atherosclerosis and coronary artery disease in diabetic
Table 1 The demographic data of patients and coronary vessel involvement. Since the total of patients is 100, numbers also present percentage relative
frequencies.
No. of involved coronary vessels Normal coronary vessels Total
Two vessels Three vessels
Sex Male 14 28 18 60
Female 5 19 16 40
Smoking Smoker 6 11 7 24
Non-smoker 8 12 56 76
Family history of CAD* positive 13 30 24 67
negative 6 17 10 33
Hypertension positive 15 38 22 75
negative 4 9 12 25
*CAD, coronary artery disease
Table 2 The mean serum level of homocysteine, HbA1c, BMI, and FBS and coronary vessel disease
Mean serum level No. of involved coronary vessels Normal coronary vessels Total
Two vessels Two vessels
Homocysteine (μmol/L) 3.6 ± 14.11 3.5*±15.39 2.7 ± 11.96 3.6 ± 13.18
HbA1c (mmol/L) 1.4 ± 7.82 1.39 ± 8.16 1.35 ± 7.89 1.38 ± 8
BMI (Kg/m2) 5.1 ± 23.48 4.6 ± 22.82 5.2 ± 24.7 4.9 ± 23.26
FBS (mg/dL) 28.4 ± 152 42.4 ± 169.7 42.3 ± 159.2 162 ± 40.2
*The difference was significant only between those with two-vessel involvement and those with normal coronary vessels
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patients, this study compared the serum homocysteine of dia-
betic patients (type II) with and without coronary artery
obstruction.
In our study, the mean serum homocysteine of diabetic
patients was 13.18 ± 3.64 μmol/L, whereas it was 13.5 ±
3.6 μmol/L and 12.78 ± 2.5 μmol/L in Hoogeveen and
Okada studies, respectively (Hoogeveen et al. 1998; Okada
et al. 1999). The difference would be explained by the differ-
ence in races and diets of the studied populations. The mean
HbA1c was 8 ± 1.38 mmol/L, while it was 8.43 ± 3.2 mmol/L
and 8.09 ± 1.75 mmol/L in Okada and Akalin studies, respec-
tively (Akalin et al. 2008; Okada et al. 1999). It is likely that
serum HbA1c is determined the most by the degree to which
blood sugar is controlled. The prevalence of coronary artery
obstruction was 66% in our study, while it was 80% and 45%
in Gazzaruso and Akalin studies, respectively (Gazzaruso
et al. 2002; Akalin et al. 2008). The difference could be due
to the difference in the studied population and also the
different criteria used for coronary angiography. As in
Gazzaruso study, the patients had been screened for silent
coronary artery disease (Gazzaruso et al. 2002).
In our study, the mean serum homocysteine of patients with
coronary artery obstruction was significantly more than that of
patients with normal coronary arteries. It was also found to be
significantly higher in patients with three-vessel involvement
than those with no involvement. However, no significant dif-
ference was found between the homocysteine level of patients
with three- and two-vessel involvement, and also those with
two and no vessel(s) involvement. In our study, only a few
patients had one-vessel involvement and because they had
evidence of milder involvement of other vessels, they were
considered among those patients with two-vessel involve-
ment. This could be because these patients were less willing
to take part in the study. In the studies of Mojiminiyi, Okada,
and Akalin, the mean serum homocysteine of patients with
coronary artery obstruction had been significantly more than
Fig. 1 Hyperhomocysteinemia in diabetic patients with coronary artery obstruction. Hyperhomocysteinemia was defined assuming different cut-offs
Table 3 Diabetes mellitus and
coronary artery obstruction Diabetes mellitus No. of involved coronary vessels Normal coronary vessels Total
Two vessels Three vessels
Age of onset
(year-old)
30–39 0 1 3 4
40–49 2 14 8 24
≥ 50 17 32 23 72
Duration
(years)
< 5 5 6 4 15
5–10 8 12 24 44
> 10 6 24 11 41
Since the total of patients is 100, numbers also present percentage relative frequencies
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that of patients with normal coronary arteries. There was also
reported a significant relationship between the number of in-
volved coronary vessels and mean serum homocysteine
(Mojiminiyi et al. 2002; Akalin et al. 2008; Okada et al.
1999). The results of Gazzaruso and Hoogeveen studies were
the same and showed a significant relationship between hy-
perhomocysteinemia and coronary artery obstruction in dia-
betic patients (type II) (Gazzaruso et al. 2002; Hoogeveen
et al. 1998). However, Audelin study only showed a signifi-
cant relationship between hyperhomocysteinemia and coro-
nary artery disease mortality in patients with diabetes mellitus
type II (Audelin and Genest 2001).
Current study showed no relationship between smoking
and coronary artery disease in diabetic patients, while in
Framingham study, smoking was established as a risk factor
of coronary artery disease. This might be because
hyperinsulinemia or hyperglycemia in diabetic patients plays
a more prominent role than smoking in the development of
atherosclerosis (Mann et al. 2014). Our study showed no re-
lationship between hypertension and BMI and coronary artery
obstruction in diabetes mellitus type II, however, Gazzaruso
study showed otherwise (Gazzaruso et al. 2002). This could
be due to the low number of patients studied. In this study,
there was no significant relationship between the age of onset
and duration of diabetes mellitus type II and mean serum
homocysteine, which is consistent with the findings of
Mojiminyi and Akalin studies (Mojiminiyi et al. 2002; Akalin
et al. 2008). However, the mean serum homocysteine was
significantly higher in patients with a duration of diabetes
more than 10 years than those with a duration between 5
and 10 years, which could be due to the non-random sampling
method of our study. It seems that the age of onset and dura-
tion of diabetes mellitus type II have no impression on the
level of serum homocysteine, and instead, diet and genetic
predisposition may play more prominent roles. This study
showed no relationship between the age of onset and duration
of diabetes mellitus type II and BMI, which is consistent with
the findings of Gazzaruso and Hoogeveen studies (Gazzaruso
et al. 2002; Hoogeveen et al. 1998).
There is more to be known about how diabetes mellitus
affects the serum level of homocysteine. The reason behind
the hyperhomocysteinemia seen in patients with diabetes
mellitus type II without nephropathy still remains unknown
(Zbidi et al. 2010; Wijekoon et al. 2007). As folate combi-
nations lower the level of serum homocysteine in these
patients, it appears that the low level of folate in these pa-
tients is a point trigger for the development of atheroscle-
rosis. As it could be a possible way to lower the risk of
coronary artery disease in patients with diabetes mellitus
type II using folate combinations, more studies are required
to be done in this regard (Okada et al. 1999; Wijekoon et al.
2007; Bondar et al. 2006).
Fig. 2 The mean serum homocysteine in different groups of diabetic patients according to the duration and age of onset
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Conclusion
The mean serum homocysteine of diabetic patients (type II)
with coronary artery obstruction was significantly higher
than that of those with normal coronary arteries. It was also
significantly higher in patients with three-vessel involve-
ment than those with no vessel involvement. There was a
significant relationship between the serum level of homo-
cysteine and coronary artery disease in patients with diabe-
tes mellitus type II.
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